Screening for Early Detection and Prevention of Pompe Disease in Israel Using Tandem Mass Spectrometry

NCT01409486 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 10000

Last updated 2011-08-04

No results posted yet for this study

Summary

The aim of the study is:

to develop a comprehensive biochemical assay for detection of Pompe disease (glycogen storage disease type II), to be implemented in the Newborn screening program among the Israeli population.

Conditions

  • Pompe Disease

Interventions

OTHER

Drawing blood spots from Newborns

Dry blood spots would be taken for determination of Alpha Glucosidase activity using LC-MS-MS

Sponsors & Collaborators

  • Rambam Health Care Campus

    lead OTHER

Eligibility

Min Age
2 Days
Max Age
7 Days
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-09-30
Primary Completion
2013-09-30
Completion
2013-09-30

Countries

  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01409486 on ClinicalTrials.gov